Literature DB >> 8728434

Confounding and exposure trends in case-crossover and case-time-control designs.

S Greenland1.   

Abstract

As with ordinary studies, both case-crossover and case-time-control studies can suffer from confounding, including confounding by indication. In a case-crossover analysis, confounding by fixed (constant) characteristics is eliminated by pairing of cases to themselves, at the possible cost of introducing bias due to time trends in exposure. A case-time-control analysis can correct case-crossover results only for bias due to such time trends. If an uncontrolled confounder (such as disease severity) is present, the use of time controls can introduce new confounding, and the case-time-control results may end up either more or less confounded than the ordinary and case-crossover results. The relative confounding in the different approaches depends on details of the relations among the unmeasured confounder, the study exposure, the study disease, and any trend in these variables or their effects. Like an ordinary study, a case-time-control study must assume absence of unmeasured confounders, whether fixed or time-varying. Like a case-crossover study, it must also assume absence of carryover effects and can be more prone to misclassification bias than an ordinary study.

Mesh:

Year:  1996        PMID: 8728434     DOI: 10.1097/00001648-199605000-00003

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  33 in total

1.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Appending epidemiological studies to conventional case-control studies (hybride case-control studies).

Authors:  Andreas Stang; Karl-Heinz Jöckel
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Applying a case-crossover study design to examine transient exposures in the transmission of N. meningitidis.

Authors:  R Reintjes; H Kajueter; I Ehrhard; U van Treeck; A Ammons
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Association between road vehicle collisions and recent medical contact in older drivers: a case-crossover study.

Authors:  Sandy Leproust; Emmanuel Lagarde; Samy Suissa; L Rachid Salmi
Journal:  Inj Prev       Date:  2007-12       Impact factor: 2.399

5.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Primary non-adherence in general practice: a Danish register study.

Authors:  Anton Pottegård; Rene dePont Christensen; Alae Houji; Camilla Binderup Christiansen; Maja Skov Paulsen; Janus Laust Thomsen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2014-04-23       Impact factor: 2.953

7.  Evidence of sample use among new users of statins: implications for pharmacoepidemiology.

Authors:  Xiaojuan Li; Til Stürmer; M Alan Brookhart
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

8.  Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection.

Authors:  Zachary Burningham; Tao He; Chia-Chen Teng; Xi Zhou; Jonathan Nebeker; Brian C Sauer
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

9.  "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.

Authors:  Shirley V Wang; Sebastian Schneeweiss; Malcolm Maclure; Joshua J Gagne
Journal:  Am J Epidemiol       Date:  2014-08-01       Impact factor: 4.897

10.  Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.